Vaccination against type 1 diabetes at the clinical trial stage
Lernmark, A.
Lakartidningen 96(11): 1300-1302
1999
ISSN/ISBN: 0023-7205 PMID: 10194908 Document Number: 510011
The occurrence of type I diabetes is associated with autoimmunity against insulin, glutamate decarboxylase (GAD65) and the transmembrane protein IA-2. Experiments in the spontaneously diabetic NOD mouse and the BB rat have shown early autoantigen treatment to confer protection from diabetes. The question remains of whether human type I diabetes can be prevented by autoantigen 'vaccination'.
Document emailed within 1 workday
Related Documents
Philips, J.C.; Scheen, A.J. 2002: Info-congress. Study of the prevention of type 1 diabetes with nicotinamide: positive lessons of a negative clinical trial (ENDIT) Revue Medicale de Liege 57(10): 672-675Galler, A.S.; Bauer, T.L. 2009: A randomised phase II trial of preoperative chemotherapy of cisplatindocetaxel or docetaxel alone for clinical stage IB/II non-small-cell lung cancer: results of a Japan Clinical Oncology Group trial (JCOG 0204) Yearbook of Oncology 2009: 194-195
Pawlowski, B.; Gries, F.A. 1991: Mumps vaccination and type-i diabetes Deutsche Medizinische Wochenschrift 116(16): 635
Krairittichai, U.; Sethakarun, S. 2017: A Randomized Controlled Trial of Seroconversion After 20 Mg versus 40 mg Intramuscular Hepatitis B Virus Vaccination in Patients with Chronic Kidney Disease Stage 3 Journal of the Medical Association of Thailand 100(Suppl 1): S1-S7
Suppapitiporn, S.; Chindavijak, B.; Onsanit, S. 2005: Effect of diabetes drug counseling by pharmacist, diabetic disease booklet and special medication containers on glycemic control of type 2 diabetes mellitus: a randomized controlled trial Journal of the Medical Association of Thailand 88 Suppl. 4: S134-S141
Kostinov, M.P.; Skochilova, T.V.; Vorob'eva, V.A.; Tarasova, A.A.; Korovkina, T.I.; Lukachev, I.V.; Iushkova, I.I.; Vaneeva, N.P. 2009: Autoantibodies after vaccination against pneumococcal and influenza infections in children and adolescents with type i diabetes mellitus Zhurnal Mikrobiologii Epidemiologii i Immunobiologii 2: 53-57
Dane, D.S.; Dick, G.W.A.; Connolly, J.H.; Fisher, O.D.; McKeown, F.; Briggs, M.; Nelson, R.; Wilson, D. 1957: Vaccination Against Poliomyelitis with Live Virus Vaccines: 1. a Trial of TN Type Ii Vaccine. 2. a Trial of SM Type i Attenuated Poliomyelitis Virus Vaccine. 3. the Evaluation of TN and SM Virus Vaccines BMJ 1(5010): 59-74
Nedogoda, S.V. 2011: Nephroprotection diabetes mellitus type 2: lessons from the ADVANCE trial Kardiologiia 51(12): 57-59
Gorus, F.K. 1996: The importance of diabetes registries and clinical biology for the study and treatment of type 1 (insulin-dependent) diabetes mellitus Verhandelingen - Koninklijke Academie Voor Geneeskunde van Belgie 58(5): 539-586
Undlien, D.E.; Joner, G.; Dahl-Jørgensen, K.; Rønningen, K.S.; Nicol-Smith, L.; Torjesen, P.A.; Søvik, O. 2000: Genetic and immunologic risks for development of type 1 diabetes--experiences from an intervention trial Tidsskrift for den Norske Laegeforening: Tidsskrift for Praktisk Medicin Ny Raekke 120(23): 2799-2803
Decraene, T.; Vandewalle, C.; Pipeleers, D.; Gorus, F.K. 1992: Increased concentrations of total IgM at clinical onset of type 1 (insulin-dependent) diabetes: correlation with IgM binding to cells. the Belgian Diabetes Registry Clinical Chemistry 38(9): 1762-1767
Sangsuwan, C.; Udompanthurak, S.; Vannasaeng, S.; Thamlikitkul, V. 2004: Randomized controlled trial of Tinospora crispa for additional therapy in patients with type 2 diabetes mellitus Journal of the Medical Association of Thailand 87(5): 543-546
Burgess, E.D.; Carides, G.W.; Gerth, W.C.; Marentette, M.A.; Chabot, I. 2004: Losartan reduces the costs associated with nephropathy and end-stage renal disease from type 2 diabetes: Economic evaluation of the RENAAL study from a Canadian perspective Canadian Journal of Cardiology 20(6): 613-618
Soonthornpun, S.; Rattarasarn, C.; Thamprasit, A.; Leetanaporn, K. 1998: Effect of acarbose in treatment of type Ii diabetes mellitus: a double-blind, crossover, placebo-controlled trial Journal of the Medical Association of Thailand 81(3): 195-200
Tatara, N.; Årsand, E.; Bratteteig, T.; Hartvigsen, G. 2013: Usage and perceptions of a mobile self-management application for people with type 2 diabetes: qualitative study of a five-month trial Studies in Health Technology and Informatics 192: 127-131
Parry-Strong, A.; Langdana, F.; Haeusler, S.; Weatherall, M.; Krebs, J. 2016: Sublingual vitamin B12 compared to intramuscular injection in patients with type 2 diabetes treated with metformin: a randomised trial New Zealand Medical Journal 129(1436): 67-75
Pánczél, P.; Hosszúfalusi, N.; Bornemisza, B.; Horváth, L.; Jánoskuti, L.; Füst, G.; Rajczy, K.; Vatay, A.; Prohászka, Z.; Madácsy, L.; Luczay, A.; Blatniczky, L.; Halmos, T.; Körner, A.; Szilvási, I.; Romics, L. 2001: Latent autoimmune diabetes in adults(LADA): part of the clinical spectrum of type-1 diabetes mellitus of autoimmune origin Orvosi Hetilap 142(46): 2571-2578
Teuscher, A. 1979: Clinical and laboratory chemical diagnosis of manifest stage diabetes Zeitschrift für Arztliche Fortbildung 73(10): 471-476
Brancati, F.L.; Whelton, P.K.; Randall, B.L.; Neaton, J.D.; Stamler, J.; Klag, M.J. 1997: Risk of end-stage renal disease in diabetes mellitus: a prospective cohort study of men screened for MRFIT. Multiple Risk Factor Intervention Trial JAMA 278(23): 2069-2074
Wadström, J.; Gannedahl, G.; Wahlberg, J.; Frödin, L.; Tedbrandt, A.; Berne, C. 1994: Development of type Ii diabetes after combined kidney-pancreas transplantation in a patient with type i (insulin-dependent) diabetes Transplantation Proceedings 26(3): 1761-1762